Benjamin Z Stanton
Overview
Explore the profile of Benjamin Z Stanton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tallan A, Kucinski J, Sunkel B, Taslim C, LaHaye S, Liu Q, et al.
bioRxiv
. 2024 Jul;
PMID: 39071412
We report a universal strategy for 2D chromatin sequencing, to increase uniform data analyses and sharing across labs, and to facilitate highly quantitative comparisons across experimental conditions. Within our system,...
2.
Kucinski J, Tallan A, Taslim C, Wang M, Cannon M, Silvius K, et al.
bioRxiv
. 2024 Jul;
PMID: 39071299
Fusion-positive rhabdomyosarcoma is an aggressive pediatric cancer molecularly characterized by arrested myogenesis. The defining genetic driver, PAX3::FOXO1, functions as a chimeric gain-of-function transcription factor. An incomplete understanding of PAX3::FOXO1's in...
3.
Stanton B, Pomella S
Front Cell Dev Biol
. 2024 Jul;
12:1416946.
PMID: 38946804
We describe exciting recent advances in fusion-driven sarcoma etiology, from an epigenetics perspective. By exploring the current state of the field, we identify and describe the central mechanisms that determine...
4.
Kim Y, Gryder B, Sinniah R, Peach M, Shern J, Abdelmaksoud A, et al.
Nat Commun
. 2024 Feb;
15(1):1703.
PMID: 38402212
Fusion-positive rhabdomyosarcoma (FP-RMS) is an aggressive pediatric sarcoma driven primarily by the PAX3-FOXO1 fusion oncogene, for which therapies targeting PAX3-FOXO1 are lacking. Here, we screen 62,643 compounds using an engineered...
5.
Sreenivas P, Wang L, Wang M, Challa A, Modi P, Hensch N, et al.
Mol Cell Biol
. 2023 Oct;
43(11):547-565.
PMID: 37882064
Rhabdomyosarcoma (RMS) is a pediatric malignancy of the muscle with characteristics of cells blocked in differentiation. is an oncogene that promotes self-renewal and blocks differentiation in the fusion negative-RMS sub-type....
6.
Wang M, Sreenivas P, Sunkel B, Wang L, Ignatius M, Stanton B
NAR Cancer
. 2023 Jun;
5(3):zcad028.
PMID: 37325549
Rhabdomyosarcoma (RMS) is a pediatric soft tissue cancer with a lack of precision therapy options for patients. We hypothesized that with a general paucity of known mutations in RMS, chromatin...
7.
Chory E, Wang M, Ceribelli M, Michalowska A, Golas S, Beck E, et al.
SLAS Discov
. 2023 Apr;
28(4):193-201.
PMID: 37121274
We report a comprehensive drug synergy study in acute myeloid leukemia (AML). In this work, we investigate a panel of cell lines spanning both MLL-rearranged and non-rearranged subtypes. The work...
8.
Tallan A, Hoffman R, Stanton B
Biochemistry
. 2023 Feb;
62(6):1111-1113.
PMID: 36848151
No abstract available.
9.
Masih K, Gardner R, Chou H, Abdelmaksoud A, Song Y, Mariani L, et al.
Blood Adv
. 2023 Jan;
7(15):4218-4232.
PMID: 36607839
CD19 chimeric antigen receptor T-cell therapy (CD19-CAR) has changed the treatment landscape and outcomes for patients with pre-B-cell acute lymphoblastic leukemia (B-ALL). Unfortunately, primary nonresponse (PNR), sustained CD19+ disease, and...
10.
Wang M, Sunkel B, Ray W, Stanton B
BMC Mol Cell Biol
. 2022 Jul;
23(1):35.
PMID: 35902807
In the past decade, we have seen the emergence of sequence-based methods to understand chromosome organization. With the confluence of in situ approaches to capture information on looping, topological domains,...